GMJ Medicine
eISSN : 2626-3041
Embase
Biosis Previews
description
Volume 3, Issue 3 (2024)
GMJM 2024, 3(3): 99-102 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2024/01/16 | Accepted: 2024/06/5 | Published: 2024/07/11
Received: 2024/01/16 | Accepted: 2024/06/5 | Published: 2024/07/11
How to cite this article
Günther J, Schneider I, Krämer A. Carvone Prevents and Alleviates Hepatic Steatosis in Rat Model with Nonalcoholic Fatty Liver Disease. GMJM 2024; 3 (3) :99-102
URL: http://gmedicine.de/article-2-228-en.html
URL: http://gmedicine.de/article-2-228-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Carvone Prevents and Alleviates Hepatic Steatosis in Rat Model with Nonalcoholic Fatty Liver Disease
1- Department of Phytochemistry, Institute for Phytochemical Research (IPR), Berlin, Germany
Abstract (557 Views)
Aims: Nonalcoholic fatty liver disease is a condition in which fat significantly aggregates in the liver, and the use of antioxidants can alleviate its adverse effects. This study aimed to evaluate the effects of carvone on hepatic steatosis and Nonalcoholic fatty liver disease by investigating the lipids in serum and liver.
Materials & Methods: Animals were grouped into four groups and studied for 42 days, including rats fed with 1) a control diet (Control), 2) a high-fat diet (HF), 3) HF+50mg/kg body weight of carvone (50 Carv) and HF+100mg/kg body weight of carvone (100 Carv). Animals were killed, and blood and liver samples were obtained to evaluate the biochemical analyses, including triglyceride, cholesterol, nonesterified fatty acids, and thiobarbituric acid-reactive substances.
Findings: Rats fed a high-fat diet showed higher levels of thiobarbituric acid-reactive substances, triglycerides, and cholesterol than the control group (p<0.05). Dietary inclusion of carvone, especially at higher levels, could reverse the effects of a high-fat diet on thiobarbituric acid-reactive substances, cholesterol, and triglycerides (p<0.05).
Conclusion: Carvone can alleviate hepatic steatosis in animals with Nonalcoholic fatty liver disease.
Materials & Methods: Animals were grouped into four groups and studied for 42 days, including rats fed with 1) a control diet (Control), 2) a high-fat diet (HF), 3) HF+50mg/kg body weight of carvone (50 Carv) and HF+100mg/kg body weight of carvone (100 Carv). Animals were killed, and blood and liver samples were obtained to evaluate the biochemical analyses, including triglyceride, cholesterol, nonesterified fatty acids, and thiobarbituric acid-reactive substances.
Findings: Rats fed a high-fat diet showed higher levels of thiobarbituric acid-reactive substances, triglycerides, and cholesterol than the control group (p<0.05). Dietary inclusion of carvone, especially at higher levels, could reverse the effects of a high-fat diet on thiobarbituric acid-reactive substances, cholesterol, and triglycerides (p<0.05).
Conclusion: Carvone can alleviate hepatic steatosis in animals with Nonalcoholic fatty liver disease.
Keywords:
| | Full-Text (HTML) (99 Views)
References
1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16): 1221-31. [Link] [DOI:10.1056/NEJMra011775]
2. Takahashi Y, Fukusato T. Pathology of nonalcoholic steatohepatitis. In: Current research in hepatology 2. Trivandrum: Research Media. 2008:99-112. [Link]
3. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatol. 1990;11(1):74-80. [Link] [DOI:10.1002/hep.1840110114]
4. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am J Gastroenterol. 2003;98(9): 2042-7. [Link] [DOI:10.1111/j.1572-0241.2003.07659.x]
5. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science. 2011;332(6037): 1519-23. [Link] [DOI:10.1126/science.1204265]
6. Misra VL, Khashab M, Chalasani N. Non-alcoholic fatty liver disease and cardiovascular risk. Curr Opin Gastroenterol Rep. 2009;11(1): 50-5. [Link] [DOI:10.1007/s11894-009-0008-4]
7. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterol. 2002;122(6): 1649-57. [Link] [DOI:10.1053/gast.2002.33573]
8. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3): 829-38. [Link] [DOI:10.1172/JCI34275]
9. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology. 2002;35(2): 367-72. [Link] [DOI:10.1053/jhep.2002.30690]
10. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31): 32345-53. [Link] [DOI:10.1074/jbc.M313478200]
11. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2009;11:188-95. [Link] [DOI:10.1111/j.1463-1326.2008.00926.x]
12. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96(2):519-25. [Link] [DOI:10.1111/j.1572-0241.2001.03553.x]
13. Harrison SA, Torgerson S, HayashiP, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485-90. [Link] [DOI:10.1111/j.1572-0241.2003.08699.x]
14. Farag RS, Daw ZY, Abo-Raya SH. Influence of some spice essential oils on Aspergilrus pamsiticus growth and production of aflatoxin in a synthetic medium. J Food Sci. 1989;54(1):74-6. [Link] [DOI:10.1111/j.1365-2621.1989.tb08571.x]
15. Saxena DB, Goswami BK, Tomar SS. Nematicidal activity of some essential oils against Meloidogyne incognita. Indian Perfum. 1987;31:150-4. [Link]
16. Zheng GQ, Kenney PM, Lam LK. Effects of carvone compounds on glutathion S-transferase activity in A/J mice. J Agric Food Chem. 1992;40:751-5. [Link] [DOI:10.1021/jf00017a008]
17. Johri RK. Cuminum cyminum and Carumcarvi: An update. Pharmacogn Rev. 2011;5(9):63-72. [Link] [DOI:10.4103/0973-7847.79101]
18. Ganji SH, Kukes GD, Lambrecht N, Kashyap ML, Kamanna VS. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2014;306(4):G320-7. [Link] [DOI:10.1152/ajpgi.00181.2013]
19. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87(1):1-16. [Link] [DOI:10.1111/j.0959-9673.2006.00465.x]
20. Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatol. 2005;42(4):905-14. [Link] [DOI:10.1002/hep.20877]
21. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: Of mice and man. Dig Dis. 2010;28(1):247-54. [Link] [DOI:10.1159/000282097]
22. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J. 2005;19(1):136-8. [Link] [DOI:10.1096/fj.04-2291fje]
23. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverse diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282(31):22678-88. [Link] [DOI:10.1074/jbc.M704213200]
24. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemiain obese mice. Hepatol. 2005;42(2):362-71. [Link] [DOI:10.1002/hep.20783]
25. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006;82(967):315-22. [Link] [DOI:10.1136/pgmj.2005.042200]
26. Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012;27(8):1341-7. [Link] [DOI:10.1111/j.1440-1746.2012.07165.x]
27. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S,et al. Therapeutic effects ofrestricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27(1):103-7. [Link] [DOI:10.1016/S0168-8278(97)80287-5]
28. Rajeshwari T, Raja B. Antioxidant and free radical scavenging effect of D-carvone in hypertensive rats. In Vivo and In Vitro study. Int Lett Nat Sci. 2015;35:6-12. [Link] [DOI:10.18052/www.scipress.com/ILNS.35.6]